Brad Thompson, PhD
Chairman, President & Chief Executive Officer
Dr. Thompson has held the positions of Chairman of the Board, President and Chief Executive Officer of Oncolytics Biotech Inc. since April 1999. He has provided leadership to various organizations within the biotechnology sector for more than twenty years. Prior to his role with Oncolytics, Dr. Thompson was the Chief Executive Officer of SYNSORB Biotech from 1994 to 1999. From 1983 to 1994, Dr. Thompson worked in a senior role at the Alberta Research Council. He is the current Chairman of BIOTECanada. He received his PhD from the University of Western Ontario in the Department of Microbiology and Immunology.
Matt Coffey, PhD
Chief Operating Officer
A co-founder of Oncolytics Biotech Inc., Dr. Coffey’s current responsibilities include directing the Company's research and development efforts, and integrating these efforts into an effective clinical trial program and intellectual property position for the Company. Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey has held the position of Chief Operations Officer of the Corporation since December 2008, Chief Operating Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.
Kirk Look, CA
Chief Financial Officer
Mr. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. He is responsible for the financial reporting and related regulatory filings, budget and treasury functions, and tax compliance of Oncolytics. Mr. Look joined Oncolytics in as the Company’s Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst & Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst & Young LLP in Chile.
Mary Ann Dillahunty, JD, MBA
Vice President, Intellectual Property
Ms. Dillahunty was a principal in the law firm of Fish & Richardson, a leading intellectual property firm in the US, from 2003 until she joined Oncolytics in 2007. In 1992, she joined the law firm of Burns, Doane, Swecker & Mathis (now part of Buchanan Ingersoll & Rooney), and subsequently became a partner in the firm. During 1996-1997, Ms. Dillahunty held the position of patent counsel to the Implant Division of ALZA Corporation. Before joining Burns Doane, she was a patent agent and law clerk with the law firm of Heller, Ehrman, White & McAuliffe. Prior to focusing her career on patent law, Ms. Dillahunty held numerous positions in the biotechnology, pharmaceutical and medical device industries, including responsibilities in regulatory affairs and research science. Ms. Dillahunty holds a B.S. in Microbiology from Michigan State University, an MBA from George Washington University, and a JD degree from Stanford Law School.
George Gill, MD
Senior Vice President, Regulatory Affairs & Chief Safety Officer
George M. Gill, MD has more than thirty years of senior-level experience in Clinical Research and Regulatory Affairs, and has supported the advancement of more than twenty products - including eleven cancer products - through the regulatory approval process in the United States, Canada and Europe. Prior to joining Oncolytics, Dr. Gill held top positions with several major pharmaceutical companies including ICI Pharmaceuticals (now AstraZeneca), The Bristol-Myers Company (now Bristol-Myers Squibb) and Hoffman-La Roche. Dr. Gill holds a BSc in Chemistry from Dickinson College in Pennsylvania and an MD from the School of Medicine at the University of Pennsylvania. He is a Board Certified pediatrician and trained in hematology-oncology at the Children's Hospital of Philadelphia (CHOP). He subsequently served on the staff at CHOP, Boston Children's Hospital and then served as Chief of Hematology-Oncology at the Children's Hospital of Newark, New Jersey.
Alan J Tuchman, MD, MBA (FAAN)
Senior Vice President, Medical and Clinical Affairs & Chief Medical Officer
Dr. Tuchman is Clinical Professor of Neurology at New York Medical College and the author of over thirty scientific papers and book chapters. He is currently in the private practice of Neurology in Manhattan and consults to a number of biotechnology and investment firms. He has served as a partner of Xmark Opportunity Partners and as Executive Chairman of Neurophysics, Inc. He was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.
Alan Warrander, PhD
Senior Vice President, Global Licensing & Business Development
In his thirty-two-year career, Dr. Warrander has held a number of positions within the biotechnology and pharmaceutical industries. Until the end of 2007, Dr. Warrander was Senior Vice President, Life Sciences at Wood Mackenzie. Prior to joining Wood Mackenzie in mid- 2005, Dr. Warrander held the position of Director of Global Licensing with AstraZeneca where he covered all aspects of partnering for the Oncology and Infection Therapeutic Areas. Before moving to Licensing in 1998, for a considerable number of years, Dr. Warrander led a Drug Metabolism/Pharmacokinetics Unit at ICI/Zeneca Pharmaceuticals. Prior to joining ICI, he had previous experience in the Drug Metabolism department of Hoechst UK and as head of the Drug Metabolism section at Sterling-Winthrop. He holds a PhD from the Department of Biochemistry at the University of Birmingham and a BSc in Chemistry and Biochemistry from the University of St. Andrews.
Learn about our lead product, REOLYSIN®, a proprietary formulation of the reovirus.